Male-specific association between a ?-secretase polymorphism and premature coronary atherosclerosis.,Male-specific association between a γ-secretase polymorphism and premature coronary atherosclerosis by Loo, K.M.J. van et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
Male-Specific Association between a c-Secretase
Polymorphism and Premature Coronary Atherosclerosis
Karen M. J. van Loo1, Tim Dejaegere2,3, Martine van Zweeden1, Jessica E. van Schijndel1, Cisca
Wijmenga4,5, Mieke D. Trip6, Gerard J. M. Martens1*
1Department of Molecular Animal Physiology, Radboud University Nijmegen, Donders Institute for Brain, Cognition and Behaviour and Nijmegen Centre for Molecular
Life Sciences (NCMLS), Nijmegen, The Netherlands, 2Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium, 3Center for Human Genetics,
KULeuven, Leuven, Belgium, 4 The Complex Genetics Section, Department of Biomedical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands,
5Department of Genetics, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands, 6Department of Cardiology, Academic Medical
Center, Amsterdam, The Netherlands
Abstract
Background: Atherosclerosis is a common multifactorial disease resulting from an interaction between susceptibility genes
and environmental factors. The causative genes that contribute to atherosclerosis are elusive. Based on recent findings with
a Wistar rat model, we speculated that the c-secretase pathway may be associated with atherosclerosis.
Methodology/Principal Findings: We have tested for association of premature coronary atherosclerosis with a non-
synonymous single-nucleotide polymorphism (SNP) in the c-secretase component APH1B (Phe217Leu; rs1047552), a SNP
previously linked to Alzheimer’s disease. Analysis of a Dutch Caucasian cohort (780 cases; 1414 controls) showed a higher
prevalence of the risk allele in the patients (odds ratio (OR) = 1.35), albeit not statistically different from the control
population. Intriguingly, after gender stratification, the difference was significant in males (OR= 1.63; p = 0.033), but not in
females (OR= 0.50; p = 0.20). Since Phe217Leu-mutated APH1B showed reduced c-secretase activity in mouse embryonic
fibroblasts, the genetic variation is likely functional.
Conclusion/Significance: We conclude that, in a male-specific manner, disturbed c-secretase signalling may play a role in
the susceptibility for premature coronary atherosclerosis.
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Introduction
Atherosclerosis is the basis of coronary artery disease and
thought to be a multifactorial disease caused by susceptibility genes
that act in concert with environmental factors. A number of
susceptibility genes have been identified (e.g. apolipoprotein E
(APOE) [1], low density lipoprotein receptor [2] and methylenete-
trahydrofolate reductase [3]), but the signalling pathways respon-
sible for vascular cell pathology are elusive. Interestingly, Wistar
rats that display a high susceptibility for the dopamine receptor
agonist apomorphine, the so-called apomorphine-susceptible
(APO-SUS) rats [4,5], show an impaired vasorelaxation to
adrenergic stimuli when compared with their phenotypic coun-
terparts APO-UNSUS rats [6,7]. Impaired vasorelaxation is
associated with an increased risk for the development of
hypertension and vascular diseases such as atherosclerosis [8].
We recently identified a gene-dosage imbalance of the c-secretase
component Aph1b as the molecular-genetic basis of the difference
between the APO-SUS and -UNSUS rats [9]. The c-secretase
enzyme complex cleaves many type I transmembrane proteins,
including the amyloid-b (Ab) precursor protein APP (known to be
involved in neuronal amyloid plaque formation in Alzheimer’s
disease [AD]), NOTCH1-4, neuregulin, low-density lipoprotein
receptor related protein (LRP1, 2 and 8) and N-cadherin [10,11].
In view of the above findings, we hypothesize that the c-
secretase pathway may be linked to atherosclerosis. Increasing
evidence suggests a link between altered vascular homeostasis, as
seen in atherosclerosis, and the neurodegenerative disease AD.
Apart from a partially overlapping epidemiology and an altered
cholesterol homeostasis, atherosclerosis and AD have also been
found to share genetic risk factors, including APOE and LRP1
[1,12–14]. Since the rare non-synonymous single-nucleotide
polymorphism (SNP) Phe217Leu (rs1047552; T.G) in the human
APH1B gene has recently been found to be associated with AD
[15], we have now tested whether this SNP is also associated with
premature coronary atherosclerosis.
Results
Male-specific association of APH1B Phe217Leu with
premature coronary atherosclerosis
Since a gene-dosage imbalance of the Aph1b gene was the
molecular-genetic basis of the APO-SUS/-UNSUS rat model [9]
and the model was characterized by a disturbed endothelium-
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dependent vascular reactivity [6,7], we tested the hypothesis that a
genetic variation in the APH1B gene may contribute to
atherosclerosis susceptibility in humans. In a Dutch case-control
cohort consisting of 780 patients with premature coronary
atherosclerosis and 1414 controls, we found a higher prevalence
of the APH1B Phe217Leu risk allele (G-allele) in the patients, albeit
not statistically different (x2 = 2.09, df=1, p= 0.15; OR=1.35;
CI = 0.90–2.01). Intriguingly, after gender stratification, the
difference was significant in the male population (x2 = 4.52,
df=1, p= 0.033; OR=1.63; CI = 1.04–2.58), whereas females
were not significantly different (x2 = 1.62, df=1, p= 0.20;
OR=0.50; CI = 0.17–1.48) (Table 1). Power analysis showed that
for the detection in the female subpopulation of a risk effect similar
to that observed in the male subpopulation, the power was
insufficient (92% power for the total population; 81% power for
the male subpopulation and 38% power for the female
subpopulation, assuming a relative risk of 1.63, a disease allele
frequency of 3.3% and a disease prevalence of 5%). All genotype
distributions tested (cases and controls) fulfilled the Hardy-
Weinberg criteria (data not shown).
Association of APH1B Leu217 with fibrinogen levels in
premature coronary atherosclerosis
We then compared the association of the APH1B Leu217 allele
with clinical parameters in the atherosclerosis patients, including
the presence of risk factors (e.g. smoking behavior and occurrence
of hypertension and diabetes mellitus), and the blood levels of lipid
compounds (e.g. cholesterol, triglycerides, and low- and high-
density lipoprotein cholesterol) (for a detailed overview of the
parameters tested, see Table 2). These parameters were not related
to the APH1B Phe217Leu variation (Table 2), except for a
significant association (p= 0.028) with the fibrinogen levels in
patients containing or lacking the APH1B Leu217 allele. Patients
without the Leu217 allele displayed fibrinogen levels of
322.8680.55 gr/l (n = 327, plus SD), whereas patients with the
Leu217 allele had levels of 375.0682.08 gr/l (n = 12, plus SD)
(Table 2); due to low female patient numbers, gender stratification
for fibrinogen levels was not possible. After Bonferroni adjustment
for multiple comparisons, however, no statistically significant
association of the fibrinogen levels with the Leu217 allele was
detected (Bonferroni’s adjustment requires a significance level of
p#0.00156).
Evolutionary conservation of amino acid residue Phe217
within the APH1 family
The degree of conservation of an amino acid within a protein
family is usually indicative of its importance for protein
functioning. A multiple sequence alignment of members of the
APH1 family (Figure 1) showed that the Phe217 residue is
conserved from plant, invertebrates, lower vertebrates, rodents
and primates to man. The various APH1 proteins all contain at
residue 217 either a phenylalanine (F) or the conservative change
to tyrosine (Y). The Support Vector Machine (SVM) score (http://
www.SNPs3D.org) [16] of 21.12 for Phe217Leu indicates a likely
impact of this substitution on APH1B protein function.
Functional analysis of the APH1B Phe217Leu
polymorphism
We wondered whether the presence of a leucine instead of the
conserved residue Phe217 of the APH1B protein would be of
functional importance. Aph1abc2/2 mouse embryonic fibroblasts
were stably transfected with human APH1B Phe217 or Leu217. c-
Secretase activity was measured by quantifying the levels of
different c-secretase substrates in cell culture extracts. We
observed a 1.6-fold reduction (p,0.05, n= 8) of c-secretase
activity towards one of its substrates, syndecan-3 [17], indicating
a subtle influence on c-secretase cleavage activity. The cleavages of
two other substrates, N-cadherin and APP, were slightly but not
significantly changed (Figure 2). Thus, in a substrate-dependent
manner the Phe217Leu substitution affected c-secretase cleavage
activity.
Discussion
In this study we show that the non-synonymous Phe217Leu
polymorphism in the human APH1B gene is a male-specific risk
factor for premature coronary atherosclerosis. The reduced c-
secretase cleavage activity of Leu217 APH1B, albeit in a substrate-
specific manner, suggests a functional relevance of this polymor-
phism. Functional consequences of reduced gene dosage of Aph1b
were also observed in the APO-SUS/-UNSUS rat model [9], an
animal model with complex features, including an impaired
vasorelaxation response to adrenergic stimuli [6,7], which
increases the risk for the development of hypertension and
vascular diseases. The gene-dosage imbalance of the Aph1b gene
Table 1. Genotype and allele frequencies for the APH1B Phe217Leu variation in a Dutch case-control study on premature coronary
atherosclerosis.
N Genotype Frequencies (%) Allele Frequencies (%) p OR
TT TG GG T G
total
controls 1414 96.0 4.0 0 98.0 2.0
patients 780 94.6 5.4 0 97.3 2.7 0.15 1.35
males
controls 938 95.9 4.1 0 98.0 2.0
patients 582 93.5 6.5 0 96.7 3.3 0.033* 1.63
females
controls 476 96.0 4.0 0 98.0 2.0
patients 198 98.0 2.0 0 99.0 1.0 0.20 0.50
Standard Chi-square tests were applied to evaluate the association with premature coronary atherosclerosis. OR =odds ratio; *p,0.05.
doi:10.1371/journal.pone.0003662.t001
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(three gene copies in APO-UNSUS rats and one or two gene
copies in APO-SUS rats) segregated with differences in c-secretase
cleavage activity and a number of other phenotypic characteristics
[9]. We therefore speculate that a subtle effect on APH1B
expression or function (copy number variation in rat or
Phe217Leu variation in human, respectively) may affect c-
secretase activity and signalling downstream of gamma-secretase
cleavage and, consequently, give rise to vascular complications.
Interestingly, the APH1B Phe217Leu polymorphism was recently
found to be also associated with AD [15]. AD pathogenesis is
frequently characterized by a peripheral vascular disturbance and
is often linked to other cholesterol/lipoprotein diseases, including
atherosclerosis [18]. In addition, cerebral atherosclerosis has been
found to be a strong contributory factor to sporadic AD
pathogenesis [19]. The APH1B Phe217Leu variation may thus
play a dual role by affecting atherosclerosis as well as AD
pathogenesis, suggesting that the two diseases have converged and
that the c-secretase signalling pathway is a susceptibility pathway
for vascular complications.
In line with the above supposition, a number of the c-secretase
substrates have been implicated in vascular pathogenesis. LRP,
which belongs to a gene family involved in mediating cellular
uptake of cholesterol-rich lipoproteins (the low-density lipoprotein
receptor (LDLR) gene family), is highly expressed in atherosclerotic
lesions [20,21] and has been shown to represent a susceptibility
gene for atherosclerosis [13]. The AD-associated c-secretase
Table 2. Clinical and biochemical characteristics of the premature coronary atherosclerosis patients with and without the APH1B
217Leu allele.
without APH1B Leu217 with APH1B Leu217 p
values6SD n values6SD n
Age (years) 43.365.3 739 42.965.3 42 0.60
BMI (kg/m2) 26.964.2 739 26.863.1 42 0.88
Age first manisfestation of vascular event (years) 41.665.9 739 40.966.1 42 0.47
Systolic blood pressure (mmHg) 129.1617.2 739 127.0618.5 42 0.45
Diastolic blood pressure (mmHg) 79.5610.5 739 81.2612.6 42 0.32
Total cholesterol prior to medication (mmol/l) 6.361.9 286 6.661.4 20 0.50
LDL-cholesterol prior to medication (mmol/l) 3.961.3 220 4.461.3 14 0.20
HDL-cholesterol prior to medication (mmol/l) 1.160.4 231 1.060.2 15 0.43
Triglycerids prior to medication (mmol/l) 1.861.2 229 1.960.7 15 0.77
Total cholesterol with medication (mmol/l) 5.061.5 738 4.961.7 42 0.88
LDL-cholesterol with medication (mmol/l) 3.061.2 730 3.161.8 41 0.78
HDL-cholesterol with medication (mmol/l) 1.160.3 737 1.160.4 42 0.41
Triglycerids with medication (mmol/l) 2.164.0 738 1.861.6 42 0.68
Apo A1 lipoprotein (mmol/l) 1.360.3 495 1.260.2 29 0.12
Apo B100 lipoprotein (mmol/l) 1.160.6 494 1.060.4 29 0.40
Lipoprotein (a) (mg/l) 215.26309.4 496 240.76377.1 30 0.66
Blood sedimentation rate (BSE) (mm/h) 10.4611.3 345 9.465.2 16 0.74
Fibrinogen (gr/l) 322.8680.5 327 375.0682.1 12 0.028 *
% n % n p
Acute myocardial infarction 73.34 739 69.05 42 0.54
Coronary angiography abnormal 98.23 621 97.14 35 0.64
Percutaneous transluminal coronary angioplasty 66.98 739 80.95 42 0.06
Coronary artery bypass grafting 7.98 739 4.76 42 0.45
Complaints claudication (,500 m walking distance) 11.77 739 7.14 42 0.36
Percutaneous transluminal angioplasty 7.58 739 7.14 42 0.92
Peripheral artery bypass grafting 2.84 739 0 42 0.27
Cerebro vascular accident 2.98 739 4.88 41 0.50
Smoking before the first event date 75.24 739 66.67 42 0.21
Treated for hypertension 25.44 735 33.33 42 0.26
Treated for diabetes mellitus 7.44 739 4.76 42 0.52
Hypercholesterolemia treatment first degree relative 48.37 552 48.57 35 0.98
Hypertension treatment first degree relative 45.71 617 47.37 38 0.84
Diabetes treatment first degree relative 27.42 660 23.08 39 0.55
Values are given as mean levels6SD or as percentages. N, number of individuals tested; BMI, body mass index; LDL, low density lipoprotein; HDL, high density
lipoprotein; Apo, apolipoprotein. *p,0.05.
doi:10.1371/journal.pone.0003662.t002
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substrate APP may be involved in vascular pathogenesis as well,
since it metabolises cholesterol [22], physically interacts with
LRP1 [23], and gives rise to the amyloid plaque constituents Ab-
40 and -42. Besides these well-studied substrates, the c-secretase
substrates NOTCH3, colony-stimulating factor 1 (CSF1), CD44,
neuregulin and ERBB4 may also be involved in the vascular
complications in patients with the APH1B Phe217Leu variation.
Mutations in NOTCH3 may cause cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoecephelopathy
(CADASIL), a syndrome characterized by systemic vascular
smooth muscle cell (VSMC) degeneration [24]. CSF1 can
contribute to atherosclerosis development via fatty streak forma-
tion and progression to complex fibrous lesions [25], and CD44
may enhance atherosclerosis pathogenesis via reactive oxygen
species [26], whereas neuregulin and ERBB4 are necessary for
vascular growth and development [27–29].
Our results show that, remarkably, only male individuals with
atherosclerosis seem to be associated with the APH1B Phe217Leu
variation. This might indicate a role for hormones or the
involvement of a Y-chromosome-linked modulation. Such a
gender-specific association has been observed for other SNPs as
well, like a male-specific association of the APOE2 and APOE4
alleles with cardiovascular disease [30]. Thus, susceptibility to
many common diseases may well be the result of complex
interactions involving gender, genes and environmental factors.
Following Bonferroni correction for multiple testing, no significant
associations between the APH1B polymorphism and plasma
lipoprotein parameters or other risk factors were observed in the
atherosclerosis patients. More detailed studies will be necessary to
establish the biochemical mechanisms underlying atherosclerosis
in patients carrying the Phe217Leu polymorphism.
In the present study, association was only tested for premature
coronary atherosclerosis, a disease with a substantial heritability
[31]. To investigate whether the Phe217Leu SNP constitutes a
susceptibility factor for other vascular complications, it would be of
interest to also test for association in elderly atherosclerotic
patients and in patients with other vascular defects (e.g.
myocardial infarction). No significant association of the APH1B
chromosomal region with coronary artery disease, myocardial
infarction or other related diseases has been found in recent
genome-wide association studies (GWAS) [32–35]. Thus, apart
from the functional Phe217Leu polymorphism, the contribution of
any additional genetic variant in the APH1B gene to the phenotype
is expected to be small. Unfortunately, no results for the APH1B
Phe217Leu polymorphism are available from the GWAS since this
polymorphism was not represented on the arrays used in these
studies. In addition, based on the data from the International
HapMap-CEU project none of the SNPs tested in the GWAS is in
near perfect proxy (r2$0.8) to the Phe217Leu polymorphism.
Therefore, the GWAS data do not provide any additional
information concerning the functional APH1B Phe217Leu SNP.
In conclusion, our results suggest that the c-secretase pathway is
a candidate pathway for premature coronary atherosclerosis and
warrant further studies on genetic variations in this pathway in
various diseases with vascular complications.
Materials and Methods
Subjects
We selected consecutive Dutch premature coronary atheroscle-
rosis patients (n = 780, age 43.365.3; 582 males, age 43.665.3
and 198 females, age 42.565.5) who qualified for inclusion after a
myocardial infarction, surgical or percutaneous coronary revas-
cularization, or a coronary angiogram with evidence of at least a
70% stenosis in a major epicardial artery (Atherosclerosis
Outpatient Clinic of the Academic Medical Center of the
University of Amsterdam). The study was approved by the
Medical Ethical Committee of the Academic Medical Center
(Amsterdam, The Netherlands) and all patients gave written
informed consent. The control subjects (n = 1414, age 51.8611.9;
Figure 1. Alignment of vertebrate and invertebrate amino acid sequences of the region within APH1 surrounding residue 217. A
black background indicates identical amino acid residues; a grey background indicates a conservative amino acid change. Abbreviations: Hs, Homo
sapiens; Pt, Pan troglodytes; Rn, Rattus norvegicus; Mm, Mus musculus; Xt, Xenopus tropicalis; Dr, Danio rerio; Dm, Drosophila melanogaster; Ce,
Caenorhabditis elegans; At, Arabidopsis thaliana. Sequences were aligned using Vector NTI (9.0) with default parameters.
doi:10.1371/journal.pone.0003662.g001
Figure 2. c-Secretase cleavage activity of human wild-type
APH1B (Phe217) and human mutant APH1B (Leu217) stably
transfected into Aph1abc2/2 mouse embryonic fibroblast cells.
The levels of the C-terminal fragments (CTFs) of N-cadherin, APP and
syndecan 3 were analysed in cells stably transfected with human APH1B
Phe217 (WT) or human APH1B Leu217 (MUT). In the MUT cells, the CTF
levels of N-cadherin and APP were slightly increased (1.1-fold and 1.2-
fold, respectively), but the difference failed to reach significance. The
levels of syndecan-3-CTF were significantly increased (1.6-fold;
p = 0.044), indicating a reduced c-secretase cleavage activity. Bars
represent quantifications of CTF signals normalized to full-length
protein levels in eight stably transfected cell lines with the average
level in WT cell lines set to 100%. *: p,0.05.
doi:10.1371/journal.pone.0003662.g002
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938 males, age 53.7610.9 and 476 females, age 48.2612.9) were
from the Sanquin Blood Bank. Volunteers were recruited at their
blood donation session at one of the collection sites of the Sanquin
Blood Bank covering the north west of the Netherlands. Therefore
more than .95% of these donors lived in the Dutch postal code
area 1000–4000. This area was chosen while the Amsterdam
patient cohort geographically overlaps the region of the blood
donor cohort serving as control donors.
Biochemical analysis
In the atherosclerosis patients, plasma cholesterol and triglyc-
erides were determined with commercially available enzymatic
methods (Boehringer Mannheim, FRG, No. 237574, and Sera-
PAK, No. 6639, respectively). To determine high-density lipopro-
tein cholesterol, the polyethylene glycol 6000 precipitation method
was used. Low-density lipoprotein cholesterol was calculated by
the Friedewald formula.
APH1B genotyping
Following the isolation of genomic DNA, APH1B (MIM#
607630) Phe217Leu genotyping was performed via allele-specific
PCR using primers specific for SNP rs1047552 (outer/general
primers: forward: 59-TGCCTTCTAGGGTTACCATCTGA-39
and reverse: 59-AGTCGGCTTTACACTGTCCCA-39. Inner/
specific primers: forward specific for the ‘‘T-allele’’: 59-AA-
TAAACCTGGCGTCAGCATTT-39 and reverse specific for
the ‘‘G-allele’’: 59-GCCCATGAGCACCAGGATTATC-39).
Generation of Aph1abc2/2 mouse embryonic fibroblast
(MEF) lines
Conditionally targeted (Aph1a and Aph1c) or classically targeted
(Aph1b) mice were described before [36]. Animals carrying a null
allele were obtained after breeding with transgenic mice expressing a
Pgk driven Cre-recombinase. Mouse embryos were dissected at E8.5
from Aph1abc+/2 crosses and genotype was determined by PCR
analysis on yolk sacs. Mouse embryonic fibroblast (MEF) cultures
were derived from dissociated Aph1abc2/2 mouse embryos [37].
Generation of stable cell lines
The Phe217 to Leu217 mutation was made using the
QuikChange II site-directed mutagenesis kit (Stratagene), using
human wild-type APH1B cloned into pcDNA3.1 Zeo+ (Invitro-
gen) as template. The primers used to introduce the mutation
were: 59-CCTGGCGTCAGCATTGATAATCCTGGTGCTC-
39 (forward); 59-GAGCACCAGGATTATCAATGCTGACGC-
CAGG-39 (reverse). Phe217 and Leu217 hAPH1B were recloned
into pMSCVpuro* and cotransfected into HEK293 cells with
helper plasmid pIK Ecopac for packaging into retroviruses.
Retroviruses were harvested and snap frozen aliquots were stored
at 280uC until use. MEF Aph1abc2/2 cells were transduced with
retrovirus for 24 hrs followed by puromycin selection in DMEM/
F12 supplemented with 10% FCS until stable lines were obtained.
Measurement of gamma-secretase activity towards
different substrates
Stably transfected MEFs were seeded and grown to confluency.
Cells were rinsed twice with ice-cold PBS and lysed in 1% Triton,
and postnuclear fractions were isolated by centrifugation at
10,000 g for 15 min at 4uC. Proteins were quantified using a
standard Bradford assay (Pierce) and 10–15 mg protein/lane was
loaded on Bis-Tris SDS-PAGE gels (Invitrogen) and transferred to
nitrocellulose membranes for Western blot detection for the
indicated proteins. Gamma-secretase activity towards each
substrate was expressed as the level of substrate C-terminal
fragment (the direct gamma-secretase substrate) relative to levels of
full-length protein. For densitometric quantification, the films were
scanned using an Image Scanner (Amersham Pharmacia) and
analyzed using ImageMaster.
Antibodies
APP was detected with C-terminal pAb B63.1 and syndecan 3
with C-terminal mAb 2E9. An antibody against the N-cadherin C-
terminus (clone 32, BD Bioscience) was purchased.
Statistical analysis
Genotype frequencies were tested for the Hardy-Weinberg
equilibrium. Differences between cases and controls were analysed
by standard contingency table analysis using two-tailed x2 test
probabilities. Odds ratios (95% confidence intervals (CI)) were
calculated as an index of the association of the APH1B genotypes
with premature atherosclerosis. Continuous and categorical
biochemical and clinical variables were determined with the
Student’s t-test and x2-analysis, respectively. A p-value,0.05 was
considered statistically significant (GraphPad Software Inc, San
Diego, CA, USA). Though being conservative, Bonferonni
correction was used to determine the significance of the
biochemical and clinical variables. Power calculations were
estimated using Quanto v1.2 [38].
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